Researchers develop multi-channel recording device for lung sound analysis

A multi-channel recording device developed at TU Graz for pathological lung sounds and associated automatic lung sound analysis could support existing screening methods for early detection of, for example, Covid-19 infections. This now requires clinical data and interdisciplinary collaboration.

They whistle, hiss and crackle. Our bodies constantly make sounds that (fortunately) are not always audible to the naked ear. The occurrence of certain noises or changes in normal sounds can be an indication of illness. Using the example of the lung, a research team at Graz University of Technology has been intensively engaged in noise recording and the development of computer-aided analysis methods as a supplement to medical diagnosis. A few months ago, the work culminated in a prototype of a multi-channel recording device and the ongoing development of an associated computer-aided diagnostic system.

The group led by Franz Pernkopf from the Institute of Signal Processing and Speech Communication now wants to further develop the system for screening Covid-19 patients. For this purpose, sound recordings of Covid-19-positive persons in clinical treatment are needed. The Austrian Science Fund (FWF) is currently reviewing an application for urgent funding of a SARS-CoV-2 call.

Objective sound assessment as a diagnostic aid

Acoustic abnormalities in the lungs are often difficult to distinguish from normal lung sounds and other body sounds such as heart and bowel sounds, speech or coughing. The short-duration sounds have a relatively low amplitude and are in the low frequency range, where the human ear has limited sensitivity and is susceptible to sonic artifacts. Listening to the lungs with a stethoscope, the traditional way, has disadvantages. The assessment of lung sounds is subjective and varies according to the experience of the medical staff. Continuous monitoring is not possible with stethoscopes - whether real or digital.

The prototype developed at TU Graz, on the other hand, allows high-quality recordings of lung sounds, on the basis of which lung diseases and pathological lung conditions can be assessed more objectively. This enables clearer examination results and thus better treatments. Pernkopf explains the technology behind it: "The lung sound recording system (LSRS) is multi-channel and equipped with very powerful micro-electromechanical microphones (MEMS). The recording of lung sounds is non-invasive; the patient simply lies on the device in the supine position." The device records the lung sounds during breathing using a total of 16 channels. The attenuation or damping of ambient and other body sounds and the quality of the recorded lung signals is crucial.

Data collection for automatic diagnosis

The LSRS records lung sounds at high quality which are further exploited for computer-aided automatic lung sound analysis. This requires a lot of data from which the system can learn. A clinical study is to help obtain correspondingly large data sets of healthy and pathological lung recordings.

Our primary focus is on the pulmonary sounds associated with pneumonia, bronchitis, pleurisy, idiopathic pulmonary fibrosis and systolic heart failure. For this we need lung sound recordings of people of all genders, different age groups and with different body mass indexes."

Franz Pernkopf, Institute of Signal Processing and Speech Communication

A clinical study in collaboration with the Medical and Pharmaceutical University in Ho Chi Min City is currently being prepared for data collection. A preliminary study on sounds associated with idiopathic pulmonary fibrosis has already been conducted in cooperation with the Medical University of Graz (Freyja Smolle-Jüttner, Clinical Department of Thoracic and Hyperbaric Surgery and Horst Olschewski, Clinical Department of Pulmonology).

Adaptation of the system to Covid-19 typical lung sounds requires appropriate recording facilities for infected persons. "We are not tied to records of lung sounds from Vietnam, of course. However, it is a question of cost as to how quickly we can move forward here. We are therefore very much hoping for funds from the FWF funding pot and are confident that we will be able to offer our cost-effective screening approach for lung diseases - including those related to Covid-19 diseases," says Pernkopf.

Supplementary tool in pre-screening

Originally, the system was developed with a view to geographical areas with no access to expensive diagnostic procedures such as MR or CT. "But even in countries with basically well-equipped clinical environments like ours, the system can be a great help: namely in pre-screening. Taking the current Covid 19 pandemic as an example, this could mean that lung sounds are also analyzed in the course of mass testing. "It is a question of the maturity of the entire system and the availability of reference data. If both are given, our system could be adapted to several lung diseases," says Pernkopf, who emphasizes at the same time: "Ideally, this will be done in cooperation with interdisciplinary research groups from the fields of medicine and technology whose work is going in a similar direction. We are grateful for additional input and open for possible cooperation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop first-of-its-kind therapy to enhance heart repair after a heart attack